关于治疗慢性肌肉骨疾病时切莱科西布安全性的现有证据:总体审查
Charlotte Beaudart1, Christian Brabant2, Majed Alokail3
1Public Health Aging Research & Epidemiology (PHARE) Group, Research Unit in Clinical, Pharmacology and Toxicology (URPC), NAmur Research Institute for LIfe Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium. charlotte.beaudart@unamur.be.
Drugs
|September 5, 2025
概括
对于慢性肌肉骨疾病,切莱科西布的胃肠道安全性比非选择性NSAID更好. 心血管和脏安全性似乎相似,但证据质量较低,需要进一步研究.
科学领域:
- 药理学和治疗学
- 证据综合和元分析
- 关节病学
背景情况:
- 慢性肌肉骨疾病,包括骨关节炎和类风湿性关节炎,显著影响生活质量.
- 非类固醇抗炎药物 (NSAID) 通常用于疼痛和炎症,但存在风险.
- 作为一种选择性COX-2抑制剂,切尔科克西布提供了一种具有潜在不同安全性特征的替代品.
研究的目的:
- 系统地综合和评估现有的关于长期肌肉骨疾病的成年人的安全性.
- 与安慰剂和非选择性NSAID相比,评估切莱科西布的胃肠道,心血管,脏和全因死亡安全性.
主要方法:
- 根据PRISMA 2020指南的总体审查方法.
- 在MEDLINE,Cochrane Central和Scopus数据库中进行全面的文献搜索.
- 使用AMSTAR-2进行偏差风险评估和使用GRADE进行证据分级的确定性.
主要成果:
- 与非选择性NSAID相比,切莱科西布的胃和胃肠道事件风险较低.
- 心血管安全结果与非选择性NSAID相似; 一项研究表明,使用赛莱科西布降低了心血管死亡风险.
- 对于全因死亡的证据是有限的,但表明潜在的风险低于非选择性NSAID.
结论:
- 与非选择性NSAID相比,切莱科西布在肌肉骨疾病中具有更高的胃肠道安全性.
- 虽然有潜在的心血管,和死亡益处,但证据不确定且有限.
- 综合随机试验和观察数据的进一步研究对于全面的长期安全评估和个性化治疗至关重要.
相关概念视频
01:21Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
01:21Skeletal Muscle Relaxants: Adverse Effects
467
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
467
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
200
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
200
01:29Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
01:31Skeletal Muscle Relaxants: Therapeutic Uses
612
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
612
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230